Article | Published:

In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates


The synergistic activity of eravacycline in combination with colistin on carbapenem-resistant A. baumannii (CRAB) isolates was evaluated in this study. Minimum inhibitory concentrations (MICs) of eravacycline and colistin were determined by the broth microdilution method. MICs values ranged between 1 to 4 mg and 0.5 to 256 mg l−1 for eravacycline and colistin, respectively. In vitro synergy between eravacycline and colistin was evaluated by using the chequerboard methodology. Synergistic activity was found in 10% of the strains, and additive effect in 30%. No antagonism was detected. Similar activity was also observed in colistin-resistant CRAB isolates. The result of this study indicates that eravacycline and colistin combination may be a potential therapeutic option for the treatment of CRAB related infections.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Paul M, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.

  2. 2.

    Aydin M, et al. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. J Hosp Infect. 2018;98:260–3.

  3. 3.

    Organization WH. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annu Rep. 2017.

  4. 4.

    Gales AC, et al. Antimicrobial susceptibility of acinetobacter calcoaceticus-acinetobacter baumannii complex and stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Open Forum Infect Dis. 2019;6:34–46.

  5. 5.

    Bonell A, et al. A systematic review and meta-analysis of ventilator-associated Pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis. 2019;68:511–8.

  6. 6.

    Resistance OWCAaEESoA. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annu Rep. 2017.

  7. 7.

    Zhang X, Gu B, Mei Y, Wen Y, Xia W. Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011. J Antibiot. 2015;68:115–20.

  8. 8.

    Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63 (1).

  9. 9.

    Vourli S, Dafopoulou K, Vrioni G, Tsakris A, Pournaras S. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2017;72:2528–30.

  10. 10.

    Nowak J, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:3277–82.

  11. 11.

    Ni W, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.

  12. 12.

    But A, et al. Analysis of epidemiology and risk factors for mortality in ventilator-associated pneumonia attacks in intensive care unit patients. Turk J Med Sci. 2017;47:812–6.

  13. 13.

    Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840–4.

  14. 14.

    Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–58.

  15. 15.

    Abdallah M, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802–5.

  16. 16.

    Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51:62–4.

  17. 17.

    Solomkin J, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224–32.

  18. 18.

    Solomkin JS, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2018.

  19. 19.

    CLSI. Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically; Approved St andard—Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

  20. 20.

    CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Wayne PCaLSI,. Performance Standards for Antimicrobial Susceptibility Testing. 28th edn. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

  21. 21.

    Hou C, Yang F. Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii. Int J Clin Exp Med. 2015;8:13859–63.

  22. 22.

    Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the Carbapenemase OXA-48. Antimicrob Agents Ch. 2012;56:559–62.

  23. 23.

    Zhou H, et al. Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. J Med Microbiol. 2007;56(Pt 8):1076–80.

  24. 24.

    Mushtaq S, et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother. 2011;66:2002–5.

  25. 25.

    Garza-Ramos U, et al. Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. Antimicrob Agents Chemother. 2008;52:2943–6.

  26. 26.

    Gomez-Gil MR, et al. Detection of KPC-2-producing Citrobacter freundii isolates in Spain. J Antimicrob Chemother. 2010;65:2695–7.

  27. 27.

    Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother. 2006;50:3396–406.

  28. 28.

    National Antimicrobial Reistance Surveillance Report, Ministery of Health General Directrote of Public Health Department,Turkey. 2017.

  29. 29.

    Amat T, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24:630–4.

  30. 30.

    Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:535–47.

  31. 31.

    Liang CA, et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24:908 1–7.

  32. 32.

    Grossman TH, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56:2559–64.

  33. 33.

    Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55–62.

  34. 34.

    Monogue ML, Thabit AK, Hamada Y, Nicolau DP. Antibacterial efficacy of eravacycline in vivo against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2016;60:5001–5.

  35. 35.

    Zhanel GG, et al. Review of Eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567–88.

  36. 36.

    Beris FS, et al. Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of Acinetobacter baumannii collected from different regions of Turkey: a multicenter study. Mikrobiyoloji Bul. 2016;50:511–21.

  37. 37.

    Pournaras S, et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents. 2017;49:749–53.

  38. 38.

    Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018; 53.383–400.

  39. 39.

    Mohammadi M, et al. Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis. Open Microbiol J. 2017;11:63–71.

Download references

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to H. Selcuk Ozger.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark